Amgen Stock Plunges 15% as Market Value Drops by $36 Billion

Amgen's stock has taken a sharp turn for the worse, plummeting 15% over five consecutive trading days. This decline in market value amounts to approximately $36 billion, leaving Amgen's market capitalization at around $204 billion.

The company's recent slide is starkly contrasted with its robust underlying business metrics. Over the last twelve months, revenue grew by 9.1%, outperforming the S&P 500 median of 8.3%. Its operating margin stands at a healthy 30.0%, significantly higher than the index median of 18.6%.

However, the stock's price-to-earnings multiple has dipped to 23.3, lower than its Health Care sector peers' median of 25.1. A free cash flow yield of 5.0% also suggests that Amgen remains a viable investment option.